Natural products as antimitotic agents

Current Topics in Medicinal Chemistry

Volumn 14, Issue 20, 2014, Pages 2272-2285

  Dall'acqua, Stefano ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anticancer; Antimitotic agents; Natural products; Tubulin

Indexed keywords

ANTIMITOTIC AGENT; CABAZITAXEL; COMBRETASTATIN; CRYPTOPHYCIN DERIVATIVE; DISCODERMOLIDE; DOCETAXEL; DOLASTATIN; DOLASTATIN 10; ELEUTHEROBIN; EPOTHILONE DERIVATIVE; HALICHONDRIN; HALIMIDE; HEMIASTERLIN; LAROTAXEL; LAULIMALIDE; NATURAL PRODUCT; NOSCAPINE; PACLITAXEL; PACLITAXEL DERIVATIVE; PACLITAXEL POLIGLUMEX; PELORUSIDE; RITUXIMAB; TACCALONOLIDE; TAXANE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT; VINCA ALKALOID; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; BIBENZYL DERIVATIVE; BIOLOGICAL PRODUCT; LIGAND; PROTEIN BINDING;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; HUMAN; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); STRUCTURE ACTIVITY RELATION; CHEMISTRY; DRUG EFFECTS; ISOLATION AND PURIFICATION; NEOPLASMS; PATHOLOGY; SYNTHESIS;

ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; BIBENZYLS; BIOLOGICAL PRODUCTS; HUMANS; LIGANDS; MICROTUBULES; NEOPLASMS; PACLITAXEL; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; VINCA ALKALOIDS;

EID: 84920622352     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666141130095311     Document Type: Article

References (130)

1. Lachance, H.; Wetzel, S.; Kumar, K.; Waldmann, H. Charting, navigating, and populating natural product chemical space for drug discovery. J. Med. Chem., 2012, 55, 5989-6001.
2. Rao, C.V.; Kurkjian, C. D.; Yamada, H. Y. Mitosis-targeting natural products for cancer prevention and therapy. Curr. Drug Targets, 2012, 13, 1820-1830.
3. Quinn, R.J.; Carroll, A.R.; Pham, N.B.; Baron, P.; Palframan, M.E.; Suraweera, L.; Pierens, G.K.; Muresan, S. Developing a drug-like natural product library. J. Nat. Prod., 2008, 71, 464-468.
4. Cragg, G.M.; Newman, D.J. Plants as a source of anti-cancer agents. J. Ethnopharmacol., 2005, 100, 72-79.
5. Cragg, G.M.; Newman, D.J. Natural products: A continuing source of novel drug leads. Biochim. Biophys. Acta Gen. Sub., 2013, 1830, 3670-3695.
6. Cragg, G.M.; Newman, D.J. A Tale of Two Tumor Targets: Topoisomerase I and Tubulin. The Wall and Wani Contribution to Cancer Chemotherapy. J. Nat. Prod., 2004, 67, 232-244.
7. Kingston, D.G.I. Tubulin-interactive natural products as anticancer agents. J. Nat. Prod., 2009, 72, 507-515.
8. Yue, Q. -.; Liu, X.; Guo, D. Microtubule-binding natural products for cancer therapy. Planta Med., 2010, 76, 1037-1043.
9. Downing, K.H.; Nogales, E. Tubulin structure: Insights into microtubule properties and functions. Curr. Opin. Struct. Biol., 1998, 8, 785-791.
10. Hait, W.N.; Rubin, E.; Alli, E.; Goodin, S. Tubulin Targeting Agents. Up. Cancer Therap., 2007, 2, 1-18.
11. Wilson, L.; Jordan, M.A. Microtubule dynamics: Taking aim at a moving target. Chem. Biol., 1995, 2, 569-573.
12. Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 2004, 4, 253-265.
13. Jordan, M.A.; Wilson, L. Microtubules and actin filaments: Dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol., 1998, 10, 123-130.
14. Jordan, M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anti Cancer Agents, 2002, 2, 1-17.
15. Kinghorn, A.D.; Su, B.; Dae, S.J.; Leng, C.C.; Lee, D.; Gu, J.; Carcache-Blanco, E.J.; Pawlus, A.D.; Sang, K.L.; Eun, J.P.; Cuendet, M.; Gills, J.J.; Bhat, K.; Park, H. -.; Mata-Greenwood, E.; Song, L.L.; Jang, M.; Pezzuto, J.M. Natural inhibitors of carcinogenesis. Planta Med., 2004, 70, 691-705.
16. Tozer, G.M.; Kanthou, C.; Baguley, B.C. Disrupting tumour blood vessels. Nat. Rev. Cancer, 2005, 5, 423-435.
17. Schwartz, E.L. Antivascular actions of microtubule-binding drugs. Clin. Cancer Res., 2009, 15, 2594-2601.
18. Marrelli, M.; Conforti, F.; Statti, G. A.; Cachet, X.; Michel, S.; Tillequin, F.; Menichini, F. Biological potential and structureactivity relationships of most recently developed vascular disrupting agents: An overview of new derivatives of natural combretastatin A-4. Curr. Med. Chem., 2011, 18, 3035-3081.
19. Svoboda, G. H.; Johnson, I.S.; Gorman, M.; Neuss, N. Current status of research on the alkaloids of Vinca rosea Linn. (Catharanthus roseus G. Don). J. Pharm. Sci., 1962, 51, 707-720.
20. Svoboda, G.H.; Gorman, M.; Barnes Jr., A.J.; Oliver, A.T. Alkaloids of Vinca rosea Linn. (Catharanthus roseus G. Don.) XII. Preparation and characterization of trace alkaloids. J. Pharm. Sci., 1962, 51, 518-523.
21. Johnson, I.S.; Armstrong, J.G.; Gorman, M.; Burnett Jr., J.P. The Vinca Alkaloids: A New Class Of Oncolytic Agents. Cancer Res., 1963, 23, 1390-1427.
22. Johnson, I.S. Historical background of Vinca alkaloid research and areas of future interest. Cancer Chemotherap. Rep. Part 1, 1968, 52, 455-461.
23. Jordan, M.A.; Thrower, D.; Wilson, L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res., 1991, 51, 2212-2222.
24. Kruczynski, A.; Barret, J.; Etiévant, C.; Colpaert, F.; Fahy, J.; Hill, B. T. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem. Pharmacol., 1998, 55, 635-648.
25. Kruczynski, A.; Colpaert, F.; Tarayre, J.; Mouillard, P.; Fahy, J.; Hill, B.T. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother. Pharmacol., 1998, 41, 437-447.
26. Zheng, J.; Deng, L.; Chen, M.; Xiao, X.; Xiao, S.; Guo, C.; Xiao, G.; Bai, L.; Ye, W.; Zhang, D.; Chen, H. Elaboration of thorough simplified vinca alkaloids as antimitotic agents based on pharmacophore similarity. Eur. J. Med. Chem., 2013, 65, 158-167.
27. Prakash, V.; Timasheff, S.N. Mechanism of interaction of vinca alkaloids with tubulin: Catharanthine and vindoline. Biochemistry, 1991, 30, 873-880.
28. Sertel, S.; Fu, Y.; Zu, Y.; Rebacz, B.; Konkimalla, B.; Plinkert, P.K.; Krämer, A.; Gertsch, J.; Efferth, T. Molecular docking and pharmacogenomics of Vinca alkaloids and their monomeric precursors, vindoline and catharanthine. Biochem. Pharmacol., 2011, 81, 723-735.
29. Agrawal, K. Vincristine. xPharm: The Comprehensive Pharmacology Reference 2011, 1-4.
30. Agrawal, K. Vinblastine. xPharm: The Comprehensive Pharmacology Reference 2011, 1-4.
31. Himes, R.H. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules. Pharmacol. Therap., 1991, 51, 257-267.
32. Burstein, H.J.; Harris, L.N.; Marcom, P.K.; Lambert-Falls, R.; Havlin, K.; Overmoyer, B.; Friedlander Jr., R.J.; Gargiulo, J.; Strenger, R.; Vogel, C.L.; Ryan, P.D.; Ellis, M.J.; Nunes, R.A.; Bunnell, C.A.; Campos, S.M.; Hallor, M.; Gelman, R.; Winer, E.P. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J. Clinical Oncol., 2003, 21, 2889-2895.
33. Burstein, H.J.; Kuter, I.; Campos, S.M.; Gelman, R.S.; Tribou, L.; Parker, L.M.; Manola, J.; Younger, J.; Matulonis, U.; Bunnell, C.A.; Partridge, A.H.; Richardson, P.G.; Clarke, K.; Shulman, L.N.; Winer, E.P. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J. Clinical Oncol., 2001, 19, 2722-2730.
34. Silverman, J.A.; Deitcher, S.R. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother. Pharmacol., 2013, 71, 555-564.
35. Hagemeister, F.; Rodriguez, M.A.; Deitcher, S.R.; Younes, A.; Fayad, L.; Goy, A.; Dang, N.H.; Forman, A.; Mclaughlin, P.; Medeiros, L.J.; Pro, B.; Romaguera, J.; Samaniego, F.; Silverman, J.A.; Sarris, A.; Cabanillas, F. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br. J. Haematol., 2013, 162, 631-638.
36. Harrison, T.S.; Lyseng-Williamson, K.A. Vincristine sulfate liposome injection: A guide to its use in refractory or relapsed acute lymphoblastic leukemia. Bio. Drugs, 2013, 27, 69-74.
37. Kaplan, L.D.; Deitcher, S.R.; Silverman, J.A.; Morgan, G. Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy. Clin. Lymphoma, Myeloma Leuk., 2014, 14 (01), 37-42.
38. O'Brien, S.; Schiller, G.; Lister, J.; Damon, L.; Goldberg, S.; Aulitzky, W.; Ben-Yehuda, D.; Stock, W.; Coutre, S.; Douer, D.; Heffner, L. T.; Larson, M.; Seiter, K.; Smith, S.; Assouline, S.; Kuriakose, P.; Maness, L.; Nagler, A.; Rowe, J.; Schaich, M.; Shpilberg, O.; Yee, K.; Schmieder, G.; Silverman, J. A.; Thomas, D.; Deitcher, S. R.; Kantarjian, H. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult philadelphia chromosome-negative acute lymphoblastic leukemia. J. Clinical Oncol., 2013, 31, 676-683.
39. Ngan, V.K.; Bellman, K.; Hill, B.T.; Wilson, L.; Jordan, M.A. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol. Pharmacol., 2001, 60, 225-232.
40. Kruczynski, A.; Hill, B.T. Vinflunine, the latest Vinca alkaloid in clinical development: A review of its preclinical anticancer properties. Crit. Rev. Oncol., 2001, 40, 159-173.
41. Kruczynski, A.; Poli, M.; Dossi, R.; Chazottes, E.; Berrichon, G.; Ricome, C.; Giavazzi, R.; Hill, B.T.; Taraboletti, G. Antiangiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur. J. Cancer, 2006, 42, 2821-2832.
42. Bennouna, J.; Delord, J.; Campone, M.; Nguyen, L. Vinflunine: A new microtubule inhibitor agent. Clin. Cancer Res., 2008, 14, 1625-1632.
43. Pettit, G.R.; Cragg, G.M.; Singh, S.B. Antineoplastic agents, 122. Constituents of Combretum caffrum. J. Nat. Prod., 1987, 50, 386-391.
44. Pettit, G.R.; Singh, S.B.; Hamel, E.; Lin, C.M.; Alberts, D.S.; Garcia-Kendal, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia, 1989, 45, 209-211.
45. Pettit, G.R.; Singh, S.B.; Niven, M.L. Isolation and structure of combretastatin D-1: A cell growth inhibitory macrocyclic lactone from Combretum caffrum. J. Am. Chem. Soc., 1988, 110, 8539-8540.
46. Pettit, G.R.; Singh, S.B.; Niven, M.L.; Hamel, E.; Schmidt, J.M. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J. Nat. Prod., 1987, 50, 119-131.
47. Pettit, G.R.; Singh, S.B.; Schmidt, J.M.; Niven, M.L.; Hamel, E.; Lin, C.M. Isolation, structure, synthesis, and antimitotic properties of combretastatins B-3 and B-4 from Combretum caffrum. J. Nat. Prod., 1988, 51, 517-527.
48. El-Zayat, A.A.E.; Degen, D.; Drabek, S.; Clark, G.M.; Pettit, G.R.; Von Hoff, D.D. In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs, 1993, 4, 19-25.
49. Lin, C.M.; Ho, H.H.; Pettit, G.R.; Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochem., 1989, 28, 6984-6991.
50. Marrelli, M.; Conforti, F.; Statti, G. A.; Cachet, X.; Michel, S.; Tillequin, F.; Menichini, F. Biological potential and structureactivity relationships of most recently developed vascular disrupting agents: An overview of new derivatives of natural combretastatin A-4. Curr. Med. Chem., 2011, 18, 3035-3081.
51. Srivastava, V.; Negi, A.S.; Kumar, J.K.; Gupta, M.M.; Khanuja, S.P.S. Plant-based anticancer molecules: A chemical and biological profile of some important leads. Bioorg. Med. Chem., 2005, 13, 5892-5908.
52. Carr, M.; Greene, L.M.; Knox, A.J.S.; Lloyd, D.G.; Zisterer, D.M.; Meegan, M.J. Lead identification of conformationally restricted ß-lactam type combretastatin analogues: Synthesis, antiproliferative activity and tubulin targeting effects. Eur. J. Med. Chem., 2010, 45, 5752-5766.
53. Siemann, D.W.; Chaplin, D.J.; Walicke, P.A. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Exp. Opin. Investig. Drugs, 2009, 18, 189-197.
54. Tron, G.C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A.A. Medicinal chemistry of combretastatin A4: Present and future directions. J. Med. Chem., 2006, 49, 3033-3044.
55. Cirla, A.; Mann, J. Combretastatins: From natural products to drug discovery. Nat. Prod. Rep., 2003, 20, 558-564.
56. Nam, N. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr. Med. Chem., 2003, 10, 1697-1722.
57. Hirata, Y.; Uemura, D. Halichondrins Antitumor Polyether Macrolides From A Marine Sponge. Pure Appl. Chem., 1986, 58, 701-710.
58. Luduena, R.F.; Roach, M.C.; Prasad, V.; Pettit, G.R. Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin. Biochem. Pharmacol., 1993, 45, 421-427.
59. Aicher, T.D.; Buszek, K.R.; Fang, F.G.; Forsyth, C.J.; Jung, S.H.; Kishi, Y.; Matelich, M.C.; Scola, P.M.; Spero, D.M.; Yoon, S.K. Total synthesis of halichondrin B and norhalichondrin B. J. Am. Chem. Soc., 1992, 114, 3162-3164.
60. Zheng, W.; Seletsky, B.M.; Palme, M.H.; Lydon, P.J.; Singer, L.A.; Chase, C.E.; Lemelin, C.A.; Shen, Y.; Davis, H.; Tremblay, L.; Towle, M.J.; Salvato, K. A.; Wels, B.F.; Aalfs, K.K.; Kishi, Y.; Littlefield, B.A.; Yu, M.J. Macrocyclic ketone analogues of halichondrin B. Bioorg. Med. Chem. Lett., 2004, 14, 5551-5554.
61. Loganzo, F.; Discafani, C.M.; Annable, T.; Beyer, C.; Musto, S.; Hari, M.; Tan, X.; Hardy, C.; Hernandez, R.; Baxter, M.; Singanallore, T.; Khafizova, G.; Poruchynsky, M.S.; Fojo, T.; Nieman, J.A.; Ayral-Kaloustian, S.; Zask, A.; Andersen, R.J.; Greenberger, L.M. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoproteinmediated resistance in vitro and in vivo. Cancer Res., 2003, 63, 1838-1845.
62. Rocha-Lima, C.M.; Bayraktar, S.; MacIntyre, J.; Raez, L.; Flores, A.M.; Ferrell, A.; Rubin, E. H.; Poplin, E.A.; Tan, A.R.; Lucarelli, A.; Zojwalla, N. A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors. Cancer, 2012, 118, 4262-4270
63. Pettit, G.R.; Kamano, Y.; Herald, C.L.; Fujii, Y.; Kizu, H.; Boyd, M.R.; Boettner, F.E.; Doubek, D.L.; Schmidt, J.M.; Chapuis, J.; Michel, C. Isolation of dolastatins 10-15 from the marine mollusc dolabella auricularia. Tetrahedron, 1993, 49, 9151-9170.
64. Pettit, G.R.; Kantoci, D.; Herald, D.L.; Barkoczy, J.; Slack, J.A. Procedures for the analyses of dolastatins 10 and 15 by high performance liquid chromatography. J. Liq. Chromatogr., 1994, 17, 191-202.
65. Hamel, E. Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol. Therapy, 1992, 55, 31-51.
66. Pettit, G.R. The dolastatins. Progress in the chemistry of organic natural products.Progrès dans la chimie des substances organiques naturelles. Fortschritte der Chemie organischer Naturstoffe. 1997, 70, 1-79.
67. Beckwith, M.; Urba, W.J.; Longo, D.L. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J. Natl. Cancer Inst., 1993, 85, 483-488.
68. Poncet, J. The dolastatins, a family of promising antineoplastic agents. Curr. Pharm. Des., 1999, 5, 139-162.
69. Watanabe, J.; Minami, M.; Kobayashi, M. Antitumor activity of TZT-1027 (soblidotin). Anticancer Res., 2006, 26, 1973-1981.
70. Natsume, T.; Watanabe, J.; Koh, Y.; Fujio, N.; Ohe, Y.; Horiuchi, T.; Saijo, N.; Nishio, K.; Kobayashi, M. Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factorsecreting human lung cancer in vivo. Cancer Sci., 2003, 94, 826-833.
71. Hashiguchi, N.; Kubota, T.; Koh, J.; Yamada, Y.; Saikawa, Y.; Otani, Y.; Watanabe, M.; Kumai, K.; Kitajima, M.; Watanabe, J.; Kobayashi, M. TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply. Anticancer Res., 2004, 24, 2201-2208.
72. Banerjee, S.; Wang, Z.; Mohammad, M.; Sarkar, F. H.; Mohammad, R.M. Efficacy of selected natural products as therapeutic agents against cancer. J. Nat. Prod., 2008, 71, 492-496.
73. Riely, G.J.; Gadgeel, S.; Rothman, I.; Saidman, B.; Sabbath, K.; Feit, K.; Kris, M.G.; Rizvi, N. A. A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer, 2007, 55, 181-185.
74. von Schwarzenberg, K.; Vollmar, A.M. Targeting apoptosis pathways by natural compounds in cancer: Marine compounds as lead structures and chemical tools for cancer therapy. Cancer Lett., 2013, 332, 295-303.
75. Al-Yahya, M.A.; Hassan, M.M.A. Noscapine. Anal. Pro. Drug Subs. Excip., 1982, 11, 407-461.
76. Smith, C.D.; Zhang, X.; Mooberry, S.L.; Patterson, G.M.L.; Moore, R.E. Cryptophycin: A new antimicrotubule agent active against drug-resistant cells. Cancer Res., 1994, 54, 3779-3784.
77. Chen, S.; Meng, L.; Ding, J. New microtubule-inhibiting anticancer agents. Exp. Opin. Investig. Drugs, 2010, 19, 329-343.
78. Bertelsen, L.B.; Shen, Y.Y.; Nielsen, T.; Stødkilde-Jørgensen, H.; Kenneth Lloyd, G.; Siemann, D.W.; Horsman, M.R. Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. Int. J. Radiat. Biol., 2011, 87, 1126-1134.
79. Petit, K.; Biard, J. Marine natural products and related compounds as anticancer agents: An overview of their clinical status. AntiCancer Agents Med. Chem., 2013, 13, 603-631.
80. Wang, Y.; Miao, Z. Marine-derived angiogenesis inhibitors for cancer therapy. Marine Drugs, 2013, 11, 903-933.
81. Wu, X.; Ma, W.; Gurung, K.; Guo, C. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: Treatment and rationale of combination therapy. J. Formosan Med. Assoc., 2013, 112, 115-124.
82. Millward, M.; Mainwaring, P.; Mita, A.; Federico, K.; Lloyd, G.K.; Reddinger, N.; Nawrocki, S.; Mita, M.; Spear, M. A. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Invest. New Drugs, 2012, 30, 1065-1073.
83. Clémenson, C.; Chargari, C.; Deutsch, E. Combination of vascular disrupting agents and ionizing radiation. Crit. Rev. Oncol., 2013, 86, 143-160.
84. Wani, M.C.; Taylor, H.L.; Wall, M.E.; Coggon, P.; McPhail, A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia [12]. J. Am. Chem. Soc., 1971, 93, 2325-2327.
85. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod., 2012, 75, 311-335.
86. Cragg, G. M.; Newman, D.J. Plants as a source of anti-cancer agents. J. Ethnopharmacol., 2005, 100, 72-79.
87. Baloglu, E.; Kingston, D.G.I. The taxane diterpenoids. J. Nat. Prod., 1999, 62, 1448-1472.
88. Nicolaou, K.C.; Dai, W.; Guy, R.K. Chemistry and biology of taxol. Angewandte Chemie (International Edition in English) 1994, 33, 15-44.
89. Schiff, P. B.; Fant, J.; Horwitz, S.B. Promotion of microtubule assembly in vitro by taxol. Nature, 1979, 277, 665-667.
90. Jordan, M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anti-Cancer Agents, 2002, 2, 1-17.
91. Fu, Y.; Li, S.; Zu, Y.; Yang, G.; Yang, Z.; Luo, M.; Jiang, S.; Wink, M.; Efferth, T. Medicinal chemistry of paclitaxel and its analogues. Curr. Med. Chem., 2009, 16, 3966-3985.
92. Nogales, E.; Wolf, S.G.; Khan, I.A.; Luduena, R.F.; Downing, K.H. Structure of tubulin at 6.5 Å and location of the taxol-binding site. Nature, 1995, 375, 424-427.
93. Nogales, E.; Wolf, S.G.; Downing, K.H. Structure of the aß tubulin dimer by electron crystallography. Nature, 1998, 391, 199-203.
94. Derry, W.B.; Wilson, L.; Jordan, M.A. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochem., 1995, 34, 2203-2211.
95. McGrogan, B.T.; Gilmartin, B.; Carney, D.N.; McCann, A. Taxanes, microtubules and chemoresistant breast cancer. Biochim. Biophy. Acta Rev. Cancer, 2008, 1785, 96-132.
96. Fumoleau, P.; Trigo, J.M.; Isambert, N.; Sémiond, D.; Gupta, S.; Campone, M. Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours. BMC Cancer, 2013, 13.
97. Boddy, A.V. Paclitaxel poliglumex: Antimitotic drug oncolytic. Drugs Fut., 2007, 32, 776-780.
98. Bonomi, P. Paclitaxel poliglumex (PPX, CT-2103): Macromolecular medicine for advanced non-small-cell lung cancer. Exp. Rev. Anticancer Therap., 2007, 7, 415-422.
99. Nyman, D.W.; Campbell, K.J.; Hersh, E.; Long, K.; Richardson, K.; Trieu, V.; Desai, N.; Hawkins, M.J.; Von Hoff, D.D. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clinical Oncol., 2005, 23, 7785-7793.
100. Gradishar, W.J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O'Shaughnessy, J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clinical Oncol., 2005, 23, 7794-7803.
101. Wartmann, M.; Altmann, K. The biology and medicinal chemistry of epothilones. Curr. Med. Chem. Anti-Cancer Agents, 2002, 2, 123-148.
102. Altaha, R.; Fojo, T.; Reed, E.; Abraham, J. Epothilones: A novel class of non-taxane microtubule-stabilizing agents. Curr. Pharm. Des., 2002, 8, 1707-1712.
103. Altmann, K. -.; Pfeiffer, B.; Arseniyadis, S.; Pratt, B.A.; Nicolaou, K. C. The chemistry and biology of epothilones The wheel keeps turning. ChemMedChem., 2007, 2, 396-423.
104. Altmann, K. -.; Flörsheimer, A.; O'Reilly, T.; Wartmann, M. The Natural Products Epothilones A and B as Lead Structures for Anticancer Drug Discovery: Chemistry, Biology, and SAR Studies. Prog.Med. Chem., 2004, 42, 171-205.
105. Altmann, K. The merger of natural product synthesis and medicinal chemistry: On the chemistry and chemical biology of epothilones. Org.Biomole. Chem., 2004, 2, 2137-2152.
106. Lee, D. Activity of epothilone B analogues ixabepilone and patupilone in hormone-refractory prostate cancer. Clinical Prost. Cancer, 2004, 3, 80-82.
107. Risinger, A.L.; Jackson, E.M.; Polin, L.A.; Helms, G. L.; LeBoeuf, D. A.; Joe, P. A.; Hopper-Borge, E.; Ludueña, R. F.; Kruh, G. D.; Mooberry, S. L. The taccalonolides: Microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res., 2008, 68, 8881-8888.
108. Peng, J.; Risinger, A. L.; Fest, G. A.; Jackson, E.M.; Helms, G.; Polin, L.A.; Mooberry, S. L. Identification and biological activities of new taccalonolide microtubule stabilizers. J. Med. Chem., 2011, 54, 6117-6124.
109. Shen, J.; Chen, Z.; Gao, Y. Taccalonolides from Tacca plantaginea. Phytochemistry, 1996, 42, 891-893.
110. Yang, J.; Zhao, R.; Chen, C.; Ni, W.; Teng, F.; Hao, X.; Liu, H. Taccalonolides W-Y, three new pentacyclic steroids from Tacca plantaginea. Helv. Chim. Acta, 2008, 91, 1077-1082.
111. Chen, Z.; Shen, J.; Gao, Y.; Wichtl, M. Five taccalonolides from Tacca plantaginea. Planta Med., 1997, 63, 40-43.
112. Risinger, A. L.; Mooberry, S. L. Taccalonolides: Novel microtubule stabilizers with clinical potential. Cancer Lett., 2010, 291, 14-19.
113. Risinger, A. L.; Li, J.; Bennett, M.J.; Rohena, C.C.; Peng, J.; Schriemer, D.C.; Mooberry, S.L. Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity. Cancer Res., 2013, 73, 6870-6892.
114. Sackett, D.L.; Fojo, T. Taccalonolides: A microtubule stabilizer poses a new puzzle with old pieces. Cell Cycle, 2011, 10, 3233-3234.
115. Tinley, T.L.; Randall-Hlubek, D.A.; Leal, R.M.; Jackson, E.M.; Cessac, J.W.; Quada Jr., J.C.; Hemscheidt, T.K.; Mooberry, S.L. Taccalonolides E and A: Plant-derived steroids with microtubulestabilizing activity. Cancer Res., 2003, 63, 3211-3220.
116. Ter Haar, E.; Kowalski, R.J.; Hamel, E.; Lin, C.M.; Longley, R.E.; Gunasekera, S.P.; Rosenkranz, H.S.; Day, B.W. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochem., 1996, 35, 243-250.
117. Hung, D.T.; Chen, J.; Schreiber, S.L. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. Chem. Biol., 1996, 3, 287-293.
118. Martello, L.A.; McDaid, H.M.; Regl, D.L.; Yang, C.H.; Meng, D.; Pettus, T.R. R.; Kaufman, M.D.; Arimoto, H.; Danishefsky, S. J.; Smith III, A. B.; Horwitz, S. B. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clinical Cancer Res., 2000, 6, 1978-1987.
119. Pettit, G.R.; Cichacz, Z.A.; Gao, F.; Boyd, M.R.; Schmidt, J. M. Isolation and structure of the cancer cell growth inhibitor dictyostatin 1. J. Chem. Soc. Seri. Chem. Communicat., 1994, 1111-1112.
120. Florence, G. J.; Gardner, N.M.; Paterson, I. Development of practical syntheses of the marine anticancer agents discodermolide and dictyostatin. Nat. Prod. Rep., 2008, 25, 342-375.
121. West, L.M.; Northcote, P.T.; Battershill, C.N. Peloruside A: A potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J. Org. Chem., 2000, 65, 445-449.
122. Hood, K. A.; West, L.M.; Rouwé, B.; Northcote, P. T.; Berridge, M.V.; Wakefield, S.J.; Miller, J.H. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res., 2002, 62, 3356-3360.
123. Hamel, E.; Day, B. W.; Miller, J.H.; Jung, M.K.; Northcote, P.T.; Ghosh, A.K.; Curran, D.P.; Cushman, M.; Nicolaou, K. C.; Paterson, I.; Sorensen, E. J. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol. Pharmacol., 2006, 70, 1555-1564.
124. Wilmes, A.; Bargh, K.; Kelly, C.; Northcote, P.T.; Miller, J.H. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines. Mole. Pharma., 2007, 4, 269-280.
125. Taylor, R.E.; Jin, M. Toward a Total Synthesis of Peloruside A: Enantioselective Preparation of the C8-C19 Region. Org. Lett., 2003, 5, 4959-4961.
126. Liao, X.; Wu, Y.; De Brabander, J.K. Total synthesis and absolute configuration of the novel microtubule-stabilizing agent peloruside A. Angew. Chem. Int. Ed., 2003, 42, 1648-1652.
127. Jin, M.; Taylor, R.E. Total synthesis of (+)-peloruside A. Org. Lett., 2005, 7, 1303-1305.
128. Ghosh, A.K.; Xu, X.; Kim, J.; Xu, C. Enantioselective total synthesis of peloruside a: A potent microtubule stabilizer. Org. Lett., 2008, 10, 1001-1004.
129. Evans, D.A.; Welch, D.S.; Speed, A. W. H.; Moniz, G. A.; Reichelt, A.; Ho, S. An aldol-based synthesis of(+)-peloruside a, a potent microtubule Stabilizing Agent. J. Am. Chem. Soc., 2009, 131, 3840-3841.
130. Singh, A.J.; Xu, C.; Xu, X.; West, L.M.; Wilmes, A.; Chan, A.; Hamel, E.; Miller, J. H.; Northcote, P. T.; Ghosh, A. K. Peloruside B, a potent antitumor macrolide from the New Zealand marine sponge Mycale hentscheli: Isolation, structure, total synthesis, and bioactivity. J. Org. Chem., 2010, 75, 2-10.